Discover our portfolio
Created by Truffle, Vexim has developed and commercialized a revolutionary spinal implant for the treatment of vertebral fractures through minimal invasive surgery.
In 2017, 6 years after the commercial launch of its SpineJack, Vexim registered sales of € 22M and 10% market share in Europe.
The company was sold in 2017 to Stryker for a total amount of € 180M.
In September 2018, the product received the FDA approval for marketing in the US.
Contact Truffle Capital
5 Rue de la Baume, 75008 Paris, France
Tel: +33 1 82 28 46 00